Castle Biosciences CSTL 深 沪
等待开盘 06-26 09:30:00 美东时间
22.91
+0.790
+3.57%
华盛通- 最 高22.91
- 今 开22.33
- 成交量 24.41万股
- 最 低 20.64
- 昨 收 22.12
- 总市值 60.16万
- 52周最高 44.28
- 市盈率 静 --
- 换手率 929.61%
- 52周最低 14.59
- 委 比 -46.38%
- 总股本 2.63万
- 历史最高 107.69
- 量 比 0.54
- 振 幅 10.26%
- 历史最低 1.10
- 每 手 1
- 风险率 7.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Castle Biosciences' i31‑SLNB Test Validates Predictive Accuracy In Melanoma Study, Supports Safe SLNB Avoidance
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the
03-09 19:12
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Castle Biosciences Announces Publication Of Expert Consensus Paper Endorsing DecisionDx-Melanoma Test
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled "31-Gene Expression
2025-12-09 20:22
Why Castle Biosciences' Rally Might Just Be Getting Started
Castle Biosciences' bullish structure is strengthening as momentum builds ahead of a possible breakout.
2025-11-05 21:02
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
2025-11-03 19:11
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences granted 66 employees RSUs covering 135,978 shares as inducement for employment, vesting over four years. The company offers innovative diagnostics for skin cancers, Barrett’s esophagus, and uveal melanoma, with R&D programs for other high-need diseases.
2025-06-19 11:00
Constellium to Exhibit at the 2025 Paris Air Show
Constellium will showcase its advanced aluminum solutions at the Paris Air Show, including its Airware® aluminum-lithium alloy designed for aerospace applications. The company will also present a recycled aluminum ingot made from end-of-life aircraft, marking a significant step in achieving a circular economy in aerospace. These innovations highlight Constellium's commitment to sustainable and efficient aviation solutions.
2025-06-16 05:00
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
Castle Biosciences' CEO Derek Maetzold will join a panel at BIO 2025 discussing challenges in commercializing precision medicine diagnostic tests. The session, titled "Advancing Innovative Risk-Stratification Tests," will focus on overcoming barriers to entry and improving patient care.
2025-06-11 11:00
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
Castle Biosciences' CEO Derek Maetzold received the 2025 Gold Stevie Lifetime Achievement Award, recognizing his transformative leadership in molecular diagnostics and precision medicine, significantly advancing patient care.
2025-06-04 11:00
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
Castle Biosciences presents study showing DecisionDx-Melanoma reduces mortality risk by 32% in melanoma patients, improving survival through precise risk assessment and personalized treatment.
2025-05-29 20:30
